Glenmark Pharmaceuticals Limited ( (IN:GLENMARK) ) has shared an update.
Glenmark Pharmaceuticals Inc., USA has launched Vancomycin Hydrochloride for Injection USP in various dosages, which is bioequivalent to Mylan Laboratories’ product. The market for this drug achieved annual sales of approximately $39.3 million, indicating a significant opportunity for Glenmark to expand its institutional portfolio in North America.
More about Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company engaged in research and development, with a strong presence in branded, generics, and OTC segments. The company focuses on therapeutic areas such as cardio-metabolic, respiratory, dermatology, and oncology. It operates 11 manufacturing facilities across four continents and is active in over 80 countries. Glenmark is recognized among the Top 100 biopharmaceutical companies and the Top 50 generics and biosimilar companies by sales.
YTD Price Performance: -4.58%
Average Trading Volume: 23,398
Current Market Cap: 434.6B INR
For detailed information about GLENMARK stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “Be the Leader You’ve Been Complaining For!” Paramount Stock (NASDAQ:PARA) Dips as Paramount Pulls Out of Politics
- Don’t “Get Rid of All Your Engine Designers”: Ford Stock (NYSE:F) Dips as it Brings Back a Big Name in Internal Combustion
- “Advanced Silicon Wafer Tests” Start; Intel Stock (NASDAQ:INTC) Slips